Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vb-201. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | GMNN | O75496 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | BLM | P54132 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.70 |
| ▸ | PRKCG | P05129 | 1/20 | 0.70 |
| ▸ | PRKCB | P05771 | 1/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.70 |
| ▸ | PRKCH | P24723 | 1/20 | 0.70 |
| ▸ | AKT1 | P31749 | 1/20 | 0.70 |
| ▸ | PRKCI | P41743 | 1/20 | 0.70 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.70 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.70 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.70 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231559 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL1963192 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| Vb-201 SCHEMBL14322398 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL2232585 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| Vb-201 SCHEMBL2071110 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL704033 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL20143296 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL704034 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL2232633 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA | |
| SCHEMBL703690 | 1.00 | RECQL (0.81) | RECQLMAPK1MEN1GMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-219918481-U | Battery direct current follows switching power supply circuit | 刘洋 | 2023-10-27 | — | — | CN | claimed |
| WO-2021199003-A1 | OXIDIZED LIPIDS AND TREATMENT OR PREVENTION OF INFLAMMATION OR INFECTIOUS DISEASE CAUSED BY CORONAVIRUS INFECTION | VASCULAR BIOGENICS LTD. (IL) | 2021-10-07 | — | — | WO | claimed |
| EP-3223824-B1 | OXIDIZED LIPIDS AND TREATMENT OR PREVENTION OF FIBROSIS | VASCULAR BIOGENICS LTD (IL) | 2021-01-06 | — | — | EP | claimed |
| EP-2791101-B1 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | VASCULAR BIOGENICS LTD (IL) | 2019-09-18 | — | — | EP | claimed |
| US-10206936-B2 | Oxidized lipids and treatment or prevention of fibrosis | VASCULAR BIOGENICS LTD. (IL) | 2019-02-19 | — | — | US | claimed |
| US-20180325928-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | VASCULAR BIOGENICS LTD. (IL) | 2018-11-15 | — | — | US | claimed |
| US-10022388-B2 | Oxidized lipids and treatment or prevention of fibrosis | VASCULAR BIOGENICS LTD. (UA) | 2018-07-17 | — | — | US | claimed |
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | claimed |
| US-20170258818-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | VASCULAR BIOGENICS LTD. (IL) | 2017-09-14 | — | — | US | claimed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | claimed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | claimed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | claimed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | claimed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | claimed |
| EP-1626728-B1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2013-07-10 | — | — | EP | claimed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | claimed |
| US-7973023-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2011-07-05 | — | — | US | claimed |
| US-7902176-B2 | Etherified oxidized phospholipids for inducing tolerance to oxidized LDL via mucosal administration; 1-hexadecyl-2-(5'-oxo-pentanyl)-sn-glycero-3-phosphocholine (D-ALLE) | VASCULAR BIOGENICS LTD. (IL) | 2011-03-08 | — | — | US | claimed |
| US-20100048515-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2010-02-25 | — | — | US | claimed |
| US-7625882-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2009-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022388-B2 | Oxidized lipids and treatment or prevention of fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885MAPK1 3896/4885MEN1 4770/4885 |
| US-20170258818-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885MAPK1 3896/4885MEN1 4770/4885 |
| US-20180325928-A1 | Oxidized Lipids and Treatment or Prevention of Fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885MAPK1 3896/4885MEN1 4770/4885 |
| US-20130079540-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | RECQL 3038/4885MAPK1 1544/4885MEN1 3752/4885 |
| US-20150216882-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | RECQL 2816/4885MAPK1 1510/4885MEN1 3857/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | RECQL 2816/4885MAPK1 1510/4885MEN1 3857/4885 |
| US-10206936-B2 | Oxidized lipids and treatment or prevention of fibrosis | CPT1A, GPX4, LIPC | RECQL 2360/4885MAPK1 3896/4885MEN1 4770/4885 |
| US-20100048515-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | ALOX15B, GPX4, ALOX12 | RECQL 3800/4885MAPK1 4288/4885MEN1 4714/4885 |
| US-20130237720-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | RECQL 2816/4885MAPK1 1510/4885MEN1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.